ArticleIndian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India2025
A follow-up Study of Effect of PDE5i Drugs on Extended High-frequency Hearing.
Article in Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphodiesterase type 5 inhibitors (PDE5i), such as Sildenafil (Viagra), Tadalafil (Cialis), and Vardenafil (Levitra), are commonly used to treat erectile dysfunction (ED) and other conditions like pulmonary hypertension and benign prostatic hyperplasia. While their therapeutic effects are well-documented, limited research exists on their potential ototoxicity. Some studies suggest that PDE5i drugs may impact hearing, potentially through the alteration of the nitric oxide pathway, which is crucial for cochlear function. Extended High-frequency audiometry (EHFA) has proven sensitive in detecting ototoxicity, making it a valuable tool for evaluating drug-induced hearing loss.The study involved 60 participants, 30 in the observational group (PDE5i users) and 30 in the control group (healthy individuals). Pre- and post-medication EHFA revealed that the observational group had significantly poorer hearing thresholds than the control group both before and after taking PDE5i drugs. The results showed that the pre-medication hearing thresholds of the observational group were already impaired, suggesting a pre-existing sensitivity to hearing loss. Post-medication, there was further deterioration in hearing thresholds.The study found that PDE5i users exhibited significantly poorer hearing sensitivity, even before taking the medication, possibly due to underlying hearing issues associated with erectile dysfunction. While the findings indicate potential ototoxic effects, further research is needed to confirm these results and explore the long-term impact. Close monitoring of hearing sensitivity in PDE5i users is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.